| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442849 | European Journal of Cancer | 2014 | 9 Pages |
Abstract
Discordance of biomarkers between the primary tumour and the corresponding relapse was seen in 10-40% of the patients, adjuvant therapies seem to drive clonal selections. Patients with tumours losing ER or PR during progression have worse survival compared with patients with retained receptor expression.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
E. Karlsson, J. Appelgren, A. Solterbeck, M. Bergenheim, V. Alvariza, J. Bergh,